S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:BCLI

Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis

$0.56
-0.04 (-6.61%)
(As of 03/28/2024 ET)
Today's Range
$0.49
$0.60
50-Day Range
$0.28
$0.66
52-Week Range
$0.13
$3.46
Volume
647,340 shs
Average Volume
962,356 shs
Market Capitalization
$27.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Brainstorm Cell Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1,670.9% Upside
$10.00 Price Target
Short Interest
Healthy
1.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
0.71mentions of Brainstorm Cell Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.70) to ($0.47) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.35 out of 5 stars

Medical Sector

145th out of 938 stocks

Biological Products, Except Diagnostic Industry

19th out of 148 stocks

BCLI stock logo

About Brainstorm Cell Therapeutics Stock (NASDAQ:BCLI)

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

BCLI Stock Price History

BCLI Stock News Headlines

A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
BCLI Mar 2024 1.500 call
Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc (BCLI)
Brainstorm Cell Therapeutics Inc. (BCLI)
BCLI Brainstorm Cell Therapeutics Inc.
BrainStorm Issues 2023 Letter to Shareholders
See More Headlines
Receive BCLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
3/28/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:BCLI
Fax
N/A
Employees
42
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+1,670.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-24,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.08) per share

Miscellaneous

Free Float
46,312,000
Market Cap
$27.66 million
Optionable
Optionable
Beta
0.22
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Chaim Lebovits (Age 53)
    President & CEO
    Comp: $990.42k
  • Dr. Stacy R. Lindborg Ph.D. (Age 54)
    Co-Chief Executive Officer
    Comp: $708.39k
  • Dr. Irit Arbel DSc (Age 64)
    Ph.D., Co-Founder & Independent Vice Chair of the Board
  • Mr. Uri Yablonka (Age 47)
    Executive VP, Chief Business Officer, Secretary & Director
  • Ms. Alla Patlis CPA (Age 37)
    M.B.A., Controller & Interim CFO
    Comp: $80k
  • Dr. Daniel Offen Ph.D.
    Chief Scientific Advisor
  • Ms. Mary Kay Turner
    Senior Vice President of Patient Advocacy & Government Affairs
  • Dr. Ibrahim Dagher M.D. (Age 55)
    Executive VP & Chief Development Officer

BCLI Stock Analysis - Frequently Asked Questions

Should I buy or sell Brainstorm Cell Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BCLI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCLI, but not buy additional shares or sell existing shares.
View BCLI analyst ratings
or view top-rated stocks.

What is Brainstorm Cell Therapeutics' stock price target for 2024?

1 brokerages have issued twelve-month price targets for Brainstorm Cell Therapeutics' shares. Their BCLI share price targets range from $10.00 to $10.00. On average, they expect the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 1,670.9% from the stock's current price.
View analysts price targets for BCLI
or view top-rated stocks among Wall Street analysts.

How have BCLI shares performed in 2024?

Brainstorm Cell Therapeutics' stock was trading at $0.2730 on January 1st, 2024. Since then, BCLI shares have increased by 106.8% and is now trading at $0.5647.
View the best growth stocks for 2024 here
.

Are investors shorting Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 850,300 shares, a decline of 20.5% from the February 29th total of 1,070,000 shares. Based on an average daily trading volume, of 1,430,000 shares, the days-to-cover ratio is currently 0.6 days.
View Brainstorm Cell Therapeutics' Short Interest
.

When is Brainstorm Cell Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our BCLI earnings forecast
.

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) released its quarterly earnings results on Tuesday, November, 14th. The biotechnology company reported ($0.14) earnings per share for the quarter, meeting the consensus estimate of ($0.14). During the same period in the previous year, the firm earned ($0.19) earnings per share.

What other stocks do shareholders of Brainstorm Cell Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Mellanox Technologies (MLNX), Caladrius Biosciences (CLBS), Abeona Therapeutics (ABEO) and Adaptimmune Therapeutics (ADAP).

Who are Brainstorm Cell Therapeutics' major shareholders?

Brainstorm Cell Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include ADAR1 Capital Management LLC (0.00%), Barclays PLC (0.00%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Brainstorm Cell Therapeutics?

Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCLI) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners